

Sudan, Republic of

**Support for Vaccine: Pneumococcal
This Decision Letter sets out the Programme Terms of a Programme.**

1. Country:	Sudan, Republic of																					
2. Vaccine grant number:	12-SDN-08a-Y, 1214-SDN-12c-X, 1516-SDN-12c-X, 17-SDN-12c-X, 1820-SDN-12c-X, 1920-SDN-12d-X																					
3. Date of Decision Letter:	30-Sep-19																					
4. Date of the Partnership Framework Agreement:	10-Dec-13																					
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine																					
6. Vaccine type:	Pneumococcal																					
7. Requested product presentation and formulation of vaccine:	PCV13, 4 dose(s) per vial, LIQUID																					
8. Programme Duration:¹	2012-2020																					
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	2012-2019	2020	2021	2022	2023	2024	Total ²															
Programme Budget (US\$)	113,310,012	5,564,000	-	-	-	-	118,874,012															
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2012</td> <td>12-SDN-08a-Y</td> <td>1,015,500</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>31 May, 2013</td> <td>1,015,500</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2012	12-SDN-08a-Y	1,015,500	Disbursement		Disbursement date	Amount (US\$)	31 May, 2013	1,015,500
Approval																						
Year	Grant Number	Amount (US\$)																				
2012	12-SDN-08a-Y	1,015,500																				
Disbursement																						
Disbursement date	Amount (US\$)																					
31 May, 2013	1,015,500																					
11. Product switch grant	Not applicable																					
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
Type of supplies to be purchased with Gavi funds	2013-2019	2020	2021																			
Number of vaccine doses		1,730,600	-																			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	114,340,012	5,564,000	-						
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.								
14. Self-procurement:	Not applicable								
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Accelerated transition phase								
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.									
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024				
Number of vaccine doses	370,800	-	-	-	-				
Number of AD syringes	388,500	-	-	-	-				
Number of re-constitution syringes	-	-	-	-	-				
Number of safety boxes	4,275	-	-	-	-				
Value of vaccine doses (US\$)	1,075,261	-	-	-	-				
Total co-financing payments (US\$) (including freight)	1,106,500	-	-	-	-				
16. Operational support for campaigns:	Not applicable								
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								

18. Financial clarifications:	Country shall provide the following clarifications to Gavi*:
Not applicable	
* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
19. Other conditions:	
Not applicable	

Signed by

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019